Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alan Ashworth

Showing results (41-50 of 434) with videos related to

Pageof 44
Sort By:
Nature Reviews. Clinical Oncology|June 30, 2018
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Alan Ashworth, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Bringing DNA repair in tumors into focusChristopher J Lord, Alan Ashworth
Current Biology : CB|January 28, 2003
X-chromosome inactivation: X marks the spot for BRCA1Caroline Stone, Nuala McCabe, Alan Ashworth
Nature Reviews. Cancer|October 29, 2004
Hallmarks of 'BRCAness' in sporadic cancersNicholas Turner, Andrew Tutt, Alan Ashworth
Expert Review of Anticancer Therapy|September 16, 2011
Therapeutic potential of PARP inhibitors for metastatic breast cancerSheeba Irshad, Alan Ashworth, Andrew Tutt
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 27, 2016
Isoflurane use is not associated with prolonged intensive care unit stay following routine cardiac surgery when compared to sevofluraneMichael Charlesworth, Alan Ashworth, Sarah Stirling
Endocrine-Related Cancer|November 30, 2007
Pregnancy and the risk of breast cancerKara Britt, Alan Ashworth, Matthew Smalley
Nature|October 1, 2010
Translating cancer research into targeted therapeuticsJ S de Bono, Alan Ashworth
Current Opinion in Pharmacology|June 16, 2005
Targeting the DNA repair defect of BRCA tumoursNicholas Turner, Andrew Tutt, Alan Ashworth
BMC Cancer|January 12, 2005
Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cellsParaic A Kenny, Tariq Enver, Alan Ashworth
Pageof 44

Showing results (41-50 of 434) with videos related to

Sort By:
Pageof 44
Nature Reviews. Clinical Oncology|June 30, 2018
Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Alan Ashworth, Christopher J Lord
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2009
Bringing DNA repair in tumors into focusChristopher J Lord, Alan Ashworth
Current Biology : CB|January 28, 2003
X-chromosome inactivation: X marks the spot for BRCA1Caroline Stone, Nuala McCabe, Alan Ashworth
Nature Reviews. Cancer|October 29, 2004
Hallmarks of 'BRCAness' in sporadic cancersNicholas Turner, Andrew Tutt, Alan Ashworth
Expert Review of Anticancer Therapy|September 16, 2011
Therapeutic potential of PARP inhibitors for metastatic breast cancerSheeba Irshad, Alan Ashworth, Andrew Tutt
Canadian Journal of Anaesthesia = Journal Canadien D'Anesthesie|October 27, 2016
Isoflurane use is not associated with prolonged intensive care unit stay following routine cardiac surgery when compared to sevofluraneMichael Charlesworth, Alan Ashworth, Sarah Stirling
Endocrine-Related Cancer|November 30, 2007
Pregnancy and the risk of breast cancerKara Britt, Alan Ashworth, Matthew Smalley
Nature|October 1, 2010
Translating cancer research into targeted therapeuticsJ S de Bono, Alan Ashworth
Current Opinion in Pharmacology|June 16, 2005
Targeting the DNA repair defect of BRCA tumoursNicholas Turner, Andrew Tutt, Alan Ashworth
BMC Cancer|January 12, 2005
Receptor and secreted targets of Wnt-1/beta-catenin signalling in mouse mammary epithelial cellsParaic A Kenny, Tariq Enver, Alan Ashworth
Pageof 44